Page last updated: 2024-08-18

isomethyleugenol and Rhabdomyosarcoma, Embryonal

isomethyleugenol has been researched along with Rhabdomyosarcoma, Embryonal in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bagella, L; Fais, M; Fiorentino, FP; Giordano, A; Marchesi, I; Sanna, L	1

Other Studies

1 other study(ies) available for isomethyleugenol and Rhabdomyosarcoma, Embryonal

Article	Year
12-O-tetradecanoylphorbol-13-acetate and EZH2 inhibition: A novel approach for promoting myogenic differentiation in embryonal rhabdomyosarcoma cells. Journal of cellular physiology, 2018, Volume: 233, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Cycle Checkpoints; Cell Differentiation; Cell Line, Tumor; Drug Synergism; Enhancer of Zeste Homolog 2 Protein; Enzyme Inhibitors; Histones; Humans; Indoles; Methylation; Muscle Development; Pyridones; Rhabdomyosarcoma, Embryonal; Signal Transduction; Tetradecanoylphorbol Acetate; Time Factors	2018

Article

Year

12-O-tetradecanoylphorbol-13-acetate and EZH2 inhibition: A novel approach for promoting myogenic differentiation in embryonal rhabdomyosarcoma cells.

Journal of cellular physiology, 2018, Volume: 233, Issue:3

Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Cycle Checkpoints; Cell Differentiation; Cell Line, Tumor; Drug Synergism; Enhancer of Zeste Homolog 2 Protein; Enzyme Inhibitors; Histones; Humans; Indoles; Methylation; Muscle Development; Pyridones; Rhabdomyosarcoma, Embryonal; Signal Transduction; Tetradecanoylphorbol Acetate; Time Factors

2018